Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD

Electrophysiology Clinical Trial

Status Not yet recruiting

Clinical Trial Summary

THis study aims to determine whether frequent dosing of intravitreal injections of Ranibizumab (Lucentis) or Bevacizumab (Avastin), which act as VEGF inhibitors, has a deleterious effect on the retina, studied by electrophysiologic testing.

This prospective, non-randomized clinical study will include patients assigned to intravitreal injection of Ranibizumab or Bevacizumab due to neovascular AMD. The patients will undergo repeat ophthalmic evaluation and intravitreal injections every 4-6 weeks, as long as will be deemed necessary. Periodic electrophysiologic evaluation including Electroretinogram (ERG), electro-oculogram (EOG) and Visual Evoked Potentials (VEP) tests will be performed every 3 months.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Electrophysiology

• NCT number: NCT00533689
• Study type: Interventional
• Source: Tel-Aviv Sourasky Medical Center
• Contact: Michaella Goldstein, MD
• Phone: +972-3-6925773
• Email: michgold@netvision.net.il
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: January 2008
• Completion date: January 2010